C1 - Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients with Advanced Neuroendocrine Tumors

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

B. El-Rayes, S. Pant, V. Villalobos, A. Hendifar, W. Chow, B. Konda, M. Reilley, A. Benson, G. Fisher, J. Starr, J. Strosberg, D. Ahn, K. Perez, N. Raj, J. Eads, T. Hobday, S. Chollate, Y. Ding, C. Fleener, J. Shorr

ABSTRACT ID: 111

C10 - Treatment Outcomes of Well- Differentiated High-Grade Neuroendocrine Tumors

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

A. Liu, B. Ueberroth, P. McGarrah, S. Buckner Petty, A. Kendi, J. Starr, T. Hobday, T. Halfdanarson, M. Sonbol

ABSTRACT ID: 143

C11 - Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

S. Wu, P. Reta-Impey, N. Manivannan, S.H. Tirumani, P. Fu, S. Cao, S. Asa, A. Kardan, F. Liu, N. Avril, P. Wojtylak, R. Lee, D. Bajor, E. Selfridge, J. Saltzman, J. Hardacre, J. Ammori, J. Winter, A. Mohamed

C14 - Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

T. Al-Toubah, E. Pelle, T. Valone, M. Haider, J. Strosberg

ABSTRACT ID: 157

C16 - Comparative Outcomes of Second Line Topoisomerase I Inhibitor- Containing Therapies on Extrapulmonary Neuroendocrine Carcinoma

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

H.-M. Yeung, K. Sreekrishnanilayam, C. Meeker, M. Deng, S. Agrawal, H. Abdullah, E. Ross, N. Vijayvergia

ABSTRACT ID: 162

C17 - The Clinical Impact of Serum Chromogranin-A in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

S. Wu, P. Reta-Impey, N. Manivannan, P. Fu, S. Cao, S. Asa, S.H. Tirumani, J. Davidson, A. Kardan, N. Avril, P. Wojtylak, D. Bajor, R. Lee, E. Selfridge, J. Saltzman, J. Ammori, J. Hardacre, J. Winter, A. Mohamed

ABSTRACT ID: 163

C18 - Avelumab in Unresectable/ Metastatic, Progressive, Grade 2-3 Neuroendocrine Neoplasms (NEN): Combined Results from NET-001 and NET-002 Trials

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

D. Chan, V. Rodriguez Freixinos, M. Doherty, K. Wasson, N. Iscoe, W. Raskin, J. Hallet, S. Myrehaug, C. Law, A. Thawer, K. Nguyen, S. Singh

ABSTRACT ID: 164

C19 - Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

B. Le, P. McGarrah, J. Whitman, A. Paciorek, N. Raj, D. Reidy-Lagunes, H. Hauser, T. Le, J. Del Rivero, A. Apolo, E. Bergsland, T. Halfdanarson

ABSTRACT ID: 185

C20 - Efficacy of Somatostatin Analog (SSA) Monotherapy for Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (NETs)

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

P. McGarrah, A. Liu, T. Hobday, J. Starr, A. Kendi, R. Graham, T. Halfdanarson, M. Sonbol

ABSTRACT ID: 200

C3 - Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome Outcomes: Interim Analyses of the XERMELO Patient Registry

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

C. Darden, V. Joish, M. Price, D. Garbinsky, S. Schwartz, C. Warner, S. Wason, P. Lapuerta

ABSTRACT ID: 113

C4 - Carcinoid Syndrome (CS) Improvements in Patients Receiving Telotristat Ethyl (TE): Findings from TELEPRO-II

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

M. Kulke, V. Di Gialleonardo, V. Joish, K. Murali, H. Kennecke

ABSTRACT ID: 115

C6 - Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: The Mayo Clinic Experience

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

J. Gile, A. Liu, P. McGarrah, R. Eiring, J. Starr, M. Sonbol, T. Hobday, T. Halfdanarson

ABSTRACT ID: 125

C8 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

M. Pavel, J. Ćwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U.-F. Pape, X.-M. Truong Thanh, A. Houchard, P. Ruszniewski

ABSTRACT ID: 135

C9 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Midgut Neuroendocrine Tumors (NETs): CLARINET FORTE Study

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

M. Pavel, J. Ćwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U.-F. Pape, X.-M. Truong Thanh, A. Houchard, P. Ruszniewski

ABSTRACT ID: 136